<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00866398</url>
  </required_header>
  <id_info>
    <org_study_id>008</org_study_id>
    <nct_id>NCT00866398</nct_id>
  </id_info>
  <brief_title>Economic Evaluation German Drug-Eluting Stent Registry</brief_title>
  <official_title>Economic Evaluation German Drug-Eluting Stent Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IKKF GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IHF Ludwigshafen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cordis Medizinische Apparate GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the advent of coronary stents, in-stent restenosis has proven to be the major
      limitation of interventional cardiology, occurring in as many as 30% of patients.
      Drug-eluting stents are specifically designed to prevent the problem of in-stent restenosis.
      They consist of a selective anti-proliferative drug, sirolimus, a controlled-release polymer,
      and a closed-cell stent delivery platform. Upon placement, sirolimus elutes into the vessel
      wall and stops the process of neointimal hyperplasia, thereby significantly reducing the
      incidence of in-stent restenosis.

      The study &quot;Economic Evaluation of the German Drug-Eluting Stent Registry&quot; examines the
      cost-effectiveness of drug-eluting stents compared to bare-metal stents (BMS) in patients
      with coronary stenosis. The goal of the study is to examine whether the guideline-supported
      implantation of SES, despite the higher initial cost, improves the quality and economic
      outcomes of the treatment of patients with coronary stenosis. Secondarily, the study
      evaluates patient quality of life, impairment of daily activities, and re-intervention rates.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cost equivalence of drug-eluting coronary stents versus bare metal stents</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACCE</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">3973</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>1 DES</arm_group_label>
    <description>Patients receiving drug-eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 BMS</arm_group_label>
    <description>Patients receiving bare metal stent</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with coronary heart disease, eligible for stent implantation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for coronary stent implantation

          -  Additional inclusion criteria BMS cohort:

               -  Acute Coronary Syndrome

               -  Diabetes Mellitus

               -  Previous Percutaneous Coronary Intervention/Coronary Artery Bypass Graft

               -  3-Vessel Disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan N Willich, Prof, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Charité University Medical Center</affiliation>
  </overall_official>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2009</study_first_submitted>
  <study_first_submitted_qc>March 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2009</study_first_posted>
  <last_update_submitted>January 14, 2011</last_update_submitted>
  <last_update_submitted_qc>January 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Stefan N Willich, MD, MPH, MBA</name_title>
    <organization>Charité - Universitätsmedizin Berlin</organization>
  </responsible_party>
  <keyword>coronary heart disease</keyword>
  <keyword>chd</keyword>
  <keyword>stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

